I

Inotiv

Global CRO for life sciences research

Histology Technician

Full-Time
No salary listed
Mid
St. Louis, MO, USA
In Person
Biology & BiotechTranslational Research & Bench Biology

About the job

Requirements
  • Certification as a Histology Technician (HT) or Histology Technician, Limited (HTL) through the American Society for Clinical Pathology, eligibility for ASCP board certification, or at least one year of relevant industry experience.
  • A high school diploma or General Educational Development (GED) credential.
  • Proficiency in processing tissue samples according to laboratory protocols.
  • Proficiency in embedding tissue into paraffin blocks.
  • Proficiency in microtomy and generating quality tissue sections.
  • Attention to detail, organizational skills, and communication skills.
  • Critical-thinking skills to recognize problems and initiate probable solution ideas.
  • Ability to multitask.
  • Ability to provide technical input as appropriate.
  • Ability to perform calibration of laboratory equipment as assigned.
  • Ability to establish and maintain positive relationships with team members, pathologists, and other staff members.
  • Ability to work effectively toward or under deadlines.
  • Ability and desire to learn new methods or workflows.
  • General knowledge of Microsoft Office, including Word, Excel, and Outlook, and the ability to learn new laboratory software.
  • Understanding of standard operating procedures and Good Laboratory Practice regulations under 21 CFR Part 58.
  • Proficiency in Microsoft Excel, Word, and Outlook.
  • Ability to read and understand applicable materials.
  • Manual dexterity to operate assigned laboratory equipment and computers.
  • Ability to read and interpret test results and instrument specifications.
  • Ability to perform frequent walking, sitting or standing for extended periods, carrying, lifting up to 50 pounds, reaching, gripping, twisting, finger control, and other repetitive motions.
  • Ability to wear latex or nitrile gloves, a dust mask or respirator, and safety glasses as required.
  • Ability to work safely around sharp objects, solvents, irritants, acids, bases, flammable materials, hazardous biological materials, and biohazards.
Responsibilities
  • Follow standard operating procedures and other applicable laboratory or company procedures.
  • Maintain confidential information in accordance with corporate policy.
  • Interact with clients, employees, and the community in a professional manner.
  • Support and participate in company initiatives.
  • Perform other duties as assigned.
  • Accurately mount tissue specimens on glass slides.
  • Examine blocks and slides macroscopically or microscopically to identify anatomical landmarks and ensure tissue preparation meets laboratory requirements.
  • Document and maintain study records to comply with applicable regulatory requirements.
  • Review and understand data associated with studies.
  • Document Good Laboratory Practice, Good Clinical Practice, and process training; provide a curriculum vitae; and keep the training file current.
  • Document study and laboratory activities as required to maintain organized and confidential study data files and specimens.
Desired Qualifications
  • Laboratory and Good Laboratory Practice experience.
  • Immunization against Hepatitis B or other diseases, if required because of exposure to hazardous biological material.

About the company

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Get referred to Inotiv

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 20, 2026 restructuring improved liquidity and strengthened Inotiv's balance sheet.
  • Q1 fiscal 2026 backlog reached $145.4 million, supporting near-term DSA revenue visibility.
  • Management kept normal operations through bankruptcy, preserving clients, vendors, and service continuity.

What critics are saying

  • June 2026 Chapter 11 cancelled existing equity, wiping out prior shareholders.
  • USDA cited Inotiv facilities in April 2026 and August 2026 for critical violations.
  • Animal-welfare scandals and bankruptcy stigma threaten customer trust and future contract wins.

What makes Inotiv unique

  • Inotiv pairs preclinical CRO services with research models and analytical capabilities.
  • July 2026 emergence from Chapter 11 cut about $326 million of debt.
  • Its VUGENE collaboration adds AI bioinformatics across Discovery and Translational Sciences.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Pension
  • Life Insurance
  • Wellbeing Program
  • Paid Time Off
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Stock Options
  • Company Equity
  • Conference Attendance Budget
  • Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

20%
Pryor Cashman
Jun 22nd, 2026
Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases.

Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases. Pryor Cashman has been engaged as counsel to Acquiom Agency Services LLC ("Acquiom"), in its roles as (i) DIP Agent for the Debtor-in-Possession Loan Credit Agreement, and (ii) administrative and collateral agent under the Prepetition First Lien Credit Agreement in the Chapter 11 bankruptcy cases of Inotiv, Inc. ("Inotiv") and its affiliated debtors. Inotiv is a contract research organization that provides drug discovery and development services to the pharmaceutical and medical device industries. On June 3, 2026, Inotiv and certain of its affiliates filed for bankruptcy protection in the United States Bankruptcy Court for the Southern District of Texas. The Pryor Cashman team representing Acquiom includes Partner Seth H. Lieberman, Chair of the Bankruptcy, Reorganization, and Creditors' Rights Group and Co-Chair of the Corporate Trust Practice; Partner Patrick Sibley, Co-Chair of the Corporate Trust Practice; Partner David W. Smith; Counsels Arsala Kidwai and Andrew S. Richmond; and Associate Daniel Brenner.seth Related people. Related services & industries. Firm Highlights Slide 1 of 10

Inotiv
Jun 3rd, 2026
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company’s existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implement a comprehensive recapitalization transaction that will strengthen its capital structure. To implement the transaction, Inotiv has filed a voluntary, prepackaged chapter

StockTitan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

StockTitan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...